Baseline Productions

Baseline Productions Net Debt/Equity

The Net Debt to Equity Ratio of Baseline Productions (BSSP) as of Nov 15, 2026 is -0.33. In the previous year, Net Debt to Equity Ratio was -0.35 — a change of -4.06% (higher).

Net Debt/Equity

-0.33

YoY

-4.06%

Last updated:

Net Debt to Equity Ratio of Baseline Productions is 2020 -0.33 . Net Debt to Equity Ratio of Baseline Productions was 2019 -0.35 . It decreases by -4.06% higher compared to the previous year.

The Baseline Productions Net Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt/Equity
Date
Net Debt/Equity
Jan 1, 2014
-0.49 USD
Jan 1, 2019
-0.35 USD
Jan 1, 2020
-0.33 USD
The Baseline Productions Net Debt/Equity history
YEARNet Debt/EquityYoY
-0.33-4.06%
-0.35-29.88%
-0.49—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Baseline Productions Stock analysis

What does Baseline Productions do? Baseline Productions Inc develops mobile based hardware and software based products. The company focuses on commercialization of its proteins for cancer and infectious disease treatments. Its Irreversible Pepsin Fraction (IPF) technology activates the immune system to fight autoimmune diseases. IPF binds to T-cells and triggers Th1 responses that eliminate infected cells. The firm's lead compound is an IPF suspension for autoimmune disease treatment including cancer, cirrhosis, and Hepatitis C. The product IMMUNE-THERAPEUTIC PROTEIN (ITP) is a therapeutic protein derived from porcine pepsin, which is irreversible, modified, and fractionated to IPF sequence. The company sells its IPF platform technology and ITP product to healthcare providers and pharmaceutical companies. Healthcare providers use IPF for immune system activation in autoimmune disease treatment. Pharmaceutical companies purchase ITP for development into therapeutic applications. The target segments include medical institutions treating autoimmune conditions and drug manufacturers seeking novel protein-based therapies. ITP is specifically indicated for cancer, cirrhosis, and Hepatitis C treatment. Baseline Productions generates revenue through licensing IPF technology and selling ITP therapeutic protein. The IPF platform is sold as a technology solution to partners in the healthcare sector. ITP is marketed as a therapeutic product for direct sale to medical facilities. The company's primary customers are healthcare institutions and pharmaceutical firms interested in immune system-based treatments for autoimmune diseases and infectious conditions. Baseline Productions is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Baseline Productions stock

Net Debt to Equity Ratio of Baseline Productions is -0.33 in 2020.

Net Debt to Equity Ratio of Baseline Productions changed from -0.35 to -0.33, representing a -4.06% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to Equity Ratio Baseline Productions since 2006 – with annual values, charts, and detailed analysis.

Net Debt/Equity adjusts the debt-to-equity ratio by subtracting cash from total debt. It provides a more accurate picture of actual leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to Equity Ratio's Baseline Productions with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Baseline Productions

All Key Metrics — Baseline Productions